|Offre||79,87 x 50000|
|Vente||80,18 x 50000|
|Var. jour||79,74 - 80,00|
|Sur 52 semaines||52,23 - 84,73|
|Volume moyen||1 179|
|Bêta (mensuel sur 5 ans)||0,41|
|Rapport P/E (sur 12 mois)||23,68|
|BPA (sur 12 mois)||S.O.|
|Date de bénéfices||S.O.|
|Dividende et rendement à terme||2,72 (3,39 %)|
|Date ex-dividende||14 mars 2023|
|Objectif sur 1 an||S.O.|
NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. "We relied on traditional Latino ...
NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ...
In the spring of 2018, North Carolina native Stephanie Walker went to her first breast cancer conference and had a revelation that she refers to as her "coming-out party." She learned she had metastatic breast cancer three years earlier and although she was a retired hospice nurse, she faced the disease without any guidance from others who shared her experience.